Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation and the Department of Defense. She is a member of the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and is a member of the cardio-oncology committee of American Heart Association. Since 2016, she has been the President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.